Ads
related to: bisacodyl delayed release tablets uspebay.com has been visited by 1M+ users in the past month
Search results
Results from the WOW.Com Content Network
Bisacodyl is an organic compound that is used as a stimulant laxative drug. It works directly on the colon to produce a bowel movement. It is typically prescribed for relief of episodic and chronic constipation and for the management of neurogenic bowel dysfunction, as well as part of bowel preparation before medical examinations, such as for a colonoscopy.
Modified-release dosage is a mechanism that (in contrast to immediate-release dosage) delivers a drug with a delay after its administration (delayed-release dosage) or for a prolonged period of time (extended-release [ER, XR, XL] dosage) or to a specific target in the body (targeted-release dosage). [1]
USP establishes documentary (written) and reference (physical) standards for medicines, food ingredients, dietary supplement products, and ingredients. These standards are used by regulatory agencies and manufacturers to help to ensure that these products are of the appropriate identity, as well as strength, quality, purity, and consistency.
A delayed release or late release may refer to: Delayed release (film), the delayed release of a film to the public; Delayed release (pharmacology), oral medicines that do not immediately disintegrate and release the active ingredient(s) into the body [+delayed release], a distinctive feature given to affricate consonants in phonology
Tablets with special coatings (for example, enteric coatings or controlled-release coatings) should not be broken before use, as this exposes the tablet core to the digestive juices, circumventing the intended delayed-release effect.
Acamprosate, sold under the brand name Campral, is a medication which reduces alcoholism cravings. [1] [5] It is thought to stabilize chemical signaling in the brain that would otherwise be disrupted by alcohol withdrawal. [6]
In the pharmaceutical industry, drug dissolution testing is routinely used to provide critical in vitro drug release information for both quality control purposes, i.e., to assess batch-to-batch consistency of solid oral dosage forms such as tablets, and drug development, i.e., to predict in vivo drug release profiles. [1]
In young, healthy volunteers, peak plasma concentrations following a single oral 4 mg immediate-release dose are reached after 1.5 hours. The elimination half-life has been determined as 18.4 hours, and may be prolonged in geriatric patients. After a 4 mg intravenous dose, the elimination half-life is approximately 24 hours.
Ads
related to: bisacodyl delayed release tablets uspebay.com has been visited by 1M+ users in the past month